<DOC>
	<DOCNO>NCT00861874</DOCNO>
	<brief_summary>The purpose study determine safety feasibility combination decitabine give fix dose escalate dos rapamycin patient relapse refractory acute myeloid leukemia .</brief_summary>
	<brief_title>A Study Decitabine Combination With Escalating Doses Rapamycin Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age great equal 18 year Diagnosis AML accord WHO criteria except acute promyelocytic leukemia AND Refractory AML define failure achieve CR 2 cycle induction chemotherapy persistence &gt; 40 % bone marrow blast one cycle chemotherapy induction OR Relapsed AML define evidence disease recurrence within 12 month achieve first CR OR Relapsed AML stem cell transplantation 100 day must elapse transplant emergence recurrent AML ECOG performance status &lt; 3 ( Appendix 1 ) Abnormal renal function evidence calculated creatinine clearance â‰¤ 30ml/min ( CockcroftGault formula ( Appendix 2 ) Abnormal liver function : Bilirubin &gt; 2.0 mg/dl , transaminase 2.5x upper limit normal Active systemic infection Known chronic liver disease Known diagnosis human immunodeficiency virus infection ( HIV ) Patients postallogeneic transplantation active GVHD great grade 1 skin Pregnant breast feed female subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>